A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Optipranolol Side Effects, and Drug Interactions - Metipranolol
Optipranolol Side Effects, and Drug Interactions - Metipranolol
SIDE EFFECTS
In clinical trials,
the use of OptiPranolol Ophthalmic Solution has been associated
with transient local
discomfort. Other ocular
adverse reactions, such as conjunctivitis,
eyelid dermatitis,
blepharitis, blurred
vision, tearing, browache, abnormal
vision, photophobia,
edema, and uveitis
have been reported in small numbers of patients, either in U.S.
clinical trials or
from post-marketing experience.
Other systemic adverse
reactions, such as allergic
reaction, headache,
asthenia, hypertension,
myocardial infarct,
atrial fibrillation,
angina, palpitation, bradycardia,
nausea, rhinitis,
dyspnea, epistaxis,
bronchitis, coughing, dizziness,
anxiety, depression,
somnolence, nervousness,
arthritis, myalgia, and rash
have also been reported in small numbers of patients.
DRUG INTERACTIONS
OptiPranolol Ophthalmic Solution should be used with caution in
patients who are receiving a beta-adrenergic blocking
agent orally, because
of the potential for additive
effects on systemic
beta-blockade.
Close observation of the patient
is recommended when a beta-blocker is administered to patients receiving
catecholamine-depleting drugs such as reserpine, because of possible
additive effects and
the production of
hypotension and/or bradycardia.
Caution should be used in the coadministration
of beta-adrenergic receptor blocking agents, such
as metipranolol, and oral
or intravenous calcium
channel antagonists, because of possible precipitation
of left ventricular failure,
and hypotension. In patients
with impaired cardiac
function, who are receiving calcium
channel antagonists,
coadministration
should be avoided.
The concomitant
use of beta-adrenergic receptor
blocking agents with
digitalis and calcium
channel antagonists
may have additive effects,
prolonging atrioventricular conduction
time.
Caution should be used in patients using concomitant
adrenergic psychotropic
drugs.
top
